Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer / 南方医科大学学报
Journal of Southern Medical University
;
(12): 446-449, 2015.
Artículo
en Chino
| WPRIM
| ID: wpr-239159
ABSTRACT
<p><b>OBJECTIVE</b>To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.</p><p><b>METHODS</b>Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). The progression-free survival, objective response rate and disease control rate were evaluated to compare the efficacy of gefitinib and erlotinib.</p><p><b>RESULTS</b>There were no significant differences in the objective response rate (P=0.711) and disease control rate (P=0.861) between the two groups. The progression-free survival of gefitinib group and erlotinib group was 8.0 months and 10.0 months, respectively. The efficacy of the two drugs was similar (P=0.293).</p><p><b>CONCLUSION</b>There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Quinazolinas
/
Carcinoma de Pulmón de Células no Pequeñas
/
Supervivencia sin Enfermedad
/
Usos Terapéuticos
/
Quimioterapia
/
Receptores ErbB
/
Clorhidrato de Erlotinib
/
Neoplasias Pulmonares
/
Metabolismo
/
Mutación
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Southern Medical University
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS